Cargando…

Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia

BACKGROUND: FLT3 mutation is present in 25–30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both as upfront treatment and in relapsed/refractory disease. Curiously, a variable proportion of wild-type FLT3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mosquera Orgueira, Adrián, Peleteiro Raíndo, Andrés, Cid López, Miguel, Antelo Rodríguez, Beatriz, Díaz Arias, José Ángel, Ferreiro Ferro, Roi, Alonso Vence, Natalia, Bendaña López, Ángeles, Abuín Blanco, Aitor, Bao Pérez, Laura, Melero Valentín, Paula, González Pérez, Marta Sonia, Cerchione, Claudio, Martinelli, Giovanni, Montesinos Fernández, Pau, Pérez Encinas, Manuel Mateo, Bello López, José Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886212/ https://www.ncbi.nlm.nih.gov/pubmed/33592069 http://dx.doi.org/10.1371/journal.pone.0247093

Ejemplares similares

Correction: Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2022)

Personalized Survival Prediction of Patients With Acute Myeloblastic Leukemia Using Gene Expression Profiling
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2021)

Detection of Rare Germline Variants in the Genomes of Patients with B-Cell Neoplasms
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2021)

Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2021)

Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2020)

Personally Tailored Survival Prediction of Patients With Follicular Lymphoma Using Machine Learning Transcriptome-Based Models
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2022)

Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2022)

Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2023)

Time to Treatment Prediction in Chronic Lymphocytic Leukemia Based on New Transcriptional Patterns
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2019)

Prognostic Stratification of Diffuse Large B-cell Lymphoma Using Clinico-genomic Models: Validation and Improvement of the LymForest-25 Model
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2022)

A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2023)

P1234: A PROGNOSTIC MODEL BASED ON GENE EXPRESSION PARAMETERS PREDICTS A BETTER RESPONSE TO BORTEZOMIB-CONTAINING IMMUNOCHEMOTHERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Mosquera-Orgueira, Adrian, et al.
Publicado: (2023)

PB2384: EVALUATION OF NEW MACHINE LEARNING SYSTEMS FOR PROGNOSTICATION BASED ON GENE EXPRESSION SIGNATURES IN MANTLE CELL AND PERIPHERAL T CELL LYMPHOMAS
por: Mosquera-Orgueira, Adrian, et al.
Publicado: (2023)

Further Activation of FLT3 Mutants by FLT3 Ligand
por: Zheng, Rui, et al.
Publicado: (2011)

The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2019)

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
por: Nagai, Kozo, et al.
Publicado: (2018)

OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
por: Eisfelder, Bartholomew J., et al.
Publicado: (2021)

Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain
por: Arenaza, Ainhoa, et al.
Publicado: (2019)

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
por: Lam, Stephen S.Y., et al.
Publicado: (2020)

Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
por: Chen, Fangli, et al.
Publicado: (2016)

Novel Mutation Hotspots within Non-Coding Regulatory Regions of the Chronic Lymphocytic Leukemia Genome
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2020)

The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors
por: Lim, Sung Hee, et al.
Publicado: (2016)

The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy
por: Cueto, Francisco J., et al.
Publicado: (2021)

Mutated Flt3Lg Provides Reduced Flt3 Recycling Compared to Wild-Type Flt3Lg and Retains the Specificity of Flt3Lg-Based CAR T-Cell Targeting in AML Models
por: Maiorova, Varvara, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: A Meta-Analysis
por: Gómez-Llobell, Marina, et al.
Publicado: (2022)

Flt3 Ligand Regulates Dendritic Cell Development from Flt3(+) Lymphoid and Myeloid-committed Progenitors to Flt3(+) Dendritic Cells In Vivo
por: Karsunky, Holger, et al.
Publicado: (2003)

Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines
por: Maiorova, Varvara, et al.
Publicado: (2021)

Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
por: Castaño-Bonilla, Tamara, et al.
Publicado: (2021)

Inhibition of FLT3 Expression by Green Tea Catechins in FLT3 Mutated-AML Cells
por: Ly, Bui Thi Kim, et al.
Publicado: (2013)

DOCK2 Interacts with FLT3 and Modulates the Survival of FLT3-Expressing Leukemia Cells
por: Wu, Min, et al.
Publicado: (2016)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3 Inhibitors
por: Smith, Catherine C., et al.
Publicado: (2015)

Altered compensatory cytokine signaling underlies the discrepancy between Flt3(–/–) and Flt3l(–/–) mice
por: Durai, Vivek, et al.
Publicado: (2018)

Wild‐type FLT3 and FLT3 ITD exhibit similar ligand‐induced internalization characteristics
por: Kellner, Fabienne, et al.
Publicado: (2020)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
por: Maiti, Abhishek, et al.
Publicado: (2021)

“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
por: Knight, Tristan E., et al.
Publicado: (2022)

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
por: Othman, Jad, et al.
Publicado: (2023)

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase
por: Weisberg, Ellen L., et al.
Publicado: (2017)

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
por: Martínez-Cuadrón, David, et al.
Publicado: (2022)

FLT3 in lineage specification and plasticity
por: Greenblatt, Sarah, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_609dqvp948qbua5hi6fsqpjmnj